eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin
Company profile
Ticker
ELOX
Exchange
Website
CEO
Robert Ward
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NAVA LEISURE USA INC, SENESCO TECHNOLOGIES INC, Sevion Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Eloxx Pharmaceuticals Ltd. • Eloxx Pharmaceuticals (AUS) Pty Ltd. • Zikani Therapeutics, Inc. ...
IRS number
841368850
ELOX stock data
Latest filings (excl ownership)
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
25-NSE
Exchange delisting
21 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
S-3
Shelf registration
24 Jan 24
S-8
Registration of securities for employees
24 Jan 24
8-K
Entry into a Material Definitive Agreement
9 Jan 24
8-K
Departure of Directors or Certain Officers
28 Dec 23
8-K
Entry into a Material Definitive Agreement
15 Dec 23
8-K
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
13 Nov 23
Transcripts
ELOX
Earnings call transcript
2020 Q4
12 Mar 21
ELOX
Earnings call transcript
2020 Q3
7 Nov 20
ELOX
Earnings call transcript
2020 Q3
5 Nov 20
ELOX
Earnings call transcript
2020 Q2
8 Aug 20
ELOX
Earnings call transcript
2020 Q1
11 May 20
ELOX
Earnings call transcript
2019 Q4
5 Mar 20
ELOX
Earnings call transcript
2019 Q3
9 Nov 19
ELOX
Earnings call transcript
2019 Q2
9 Aug 19
ELOX
Earnings call transcript
2019 Q1
10 May 19
ELOX
Earnings call transcript
2018 Q4
8 Mar 19
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.99 mm | 4.99 mm | 4.99 mm | 4.99 mm | 4.99 mm | 4.99 mm |
Cash burn (monthly) | (no burn) | 1.65 mm | 1.21 mm | 1.61 mm | 1.15 mm | 1.50 mm |
Cash used (since last report) | n/a | 11.33 mm | 8.31 mm | 11.02 mm | 7.89 mm | 10.28 mm |
Cash remaining | n/a | -6.33 mm | -3.32 mm | -6.03 mm | -2.89 mm | -5.29 mm |
Runway (months of cash) | n/a | -3.8 | -2.7 | -3.8 | -2.5 | -3.5 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 0 |
Closed positions | 4 |
Increased positions | 3 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 744.88 mm |
Total shares | 15.21 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Pontifax Management III G.P. | 7.46 mm | $10.52 mm |
Gurnet Point | 4.98 mm | $7.02 mm |
Advent Life Sciences | 2.53 mm | $8.51 mm |
Silverarc Capital Management | 54.08 k | $210.35 mm |
Menora Mivtachim | 52.36 k | $203.66 mm |
AFG American Financial | 37.00 k | $144.00 k |
Altshuler Shaham | 25.12 k | $97.73 mm |
Vanguard | 20.69 k | $80.47 mm |
Geode Capital Management | 20.26 k | $78.81 mm |
Clal Insurance Enterprises | 14.63 k | $57.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jan 24 | Sumit Aggarwal | RSU Common Stock | Grant | Acquire A | No | No | 0 | 60,000 | 0.00 | 60,000 |
24 Jan 24 | Alan Edmund Walts | RSU Common Stock | Grant | Acquire A | No | No | 0 | 7,500 | 0.00 | 7,500 |
24 Jan 24 | Rubin Steven D | RSU Common Stock | Grant | Acquire A | No | No | 0 | 7,500 | 0.00 | 7,500 |
24 Jan 24 | Lindsay Androski | RSU Common Stock | Grant | Acquire A | No | No | 0 | 7,500 | 0.00 | 7,500 |
30 Jan 23 | Kariv Tomer | Stock Options Common Stock | Grant | Acquire A | No | No | 4 | 2,859 | 11.44 k | 2,859 |
Press releases
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
16 Apr 24
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
13 Mar 24
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
13 Mar 24